Completed PHASE2 INTERVENTIONAL 1-arm NCT01045889

High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk (HDT-HIV)

First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at High Risk, Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation

Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Conditions HIV Infections HIV-related Lymphoma

Interventions Rituximab and CHOP regimen + PBSCT

Updated 6 times since 2017 Last updated: Aug 18, 2016 Started: Jan 31, 2007 Primary completion: May 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01045889, this PHASE2 trial focuses on HIV Infections and HIV-related Lymphoma and remains completed. Sponsored by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
May 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — May 2020 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Data source: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brescia, Italy